Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) traded up 5.8% during mid-day trading on Wednesday . The stock traded as high as $33.63 and last traded at $33.32. Approximately 61,732 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 265,036 shares. The stock had previously closed at $31.49.
Analyst Ratings Changes
A number of brokerages recently commented on COAG. Evercore began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Hemab Therapeutics in a research report on Friday, June 26th. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.40.
Read Our Latest Research Report on Hemab Therapeutics
Hemab Therapeutics Trading Up 9.6%
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.
Insiders Place Their Bets
In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the purchase, the insider owned 6,444,637 shares in the company, valued at $160,987,032.26. This trade represents a 0.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 2,970,541 shares of company stock worth $55,459,603.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Articles
- Five stocks we like better than Hemab Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
